USANA Health Sciences (NYSE:USNA) Releases FY 2026 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.760-0.760 for the period, compared to the consensus EPS estimate of 2.120. The company issued revenue guidance of $910.0 million-$910.0 million, compared to the consensus revenue estimate of $945.1 million.

USANA Health Sciences Stock Down 34.4%

NYSE:USNA traded down $7.83 during mid-day trading on Wednesday, reaching $14.95. 405,789 shares of the company were exchanged, compared to its average volume of 121,585. The stock has a market cap of $275.94 million, a PE ratio of 31.86, a PEG ratio of 0.90 and a beta of 0.73. USANA Health Sciences has a 12 month low of $14.76 and a 12 month high of $32.32. The company has a fifty day moving average of $20.62 and a 200 day moving average of $19.79.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The company had revenue of $223.27 million during the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, equities research analysts anticipate that USANA Health Sciences will post 2.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on USNA shares. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Wednesday, June 24th. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. Finally, Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

Insider Buying and Selling

In other news, insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $19.82, for a total transaction of $75,137.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the sale, the director owned 4,230 shares in the company, valued at $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 17,660 shares of company stock valued at $336,579 in the last three months. 0.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its stake in shares of USANA Health Sciences by 1.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after buying an additional 21,793 shares in the last quarter. Vanguard Group Inc. grew its position in shares of USANA Health Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after acquiring an additional 57,249 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of USANA Health Sciences by 1.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after purchasing an additional 17,318 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in USANA Health Sciences in the 4th quarter valued at about $11,485,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in USANA Health Sciences by 22.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 353,946 shares of the company’s stock worth $6,948,000 after purchasing an additional 65,867 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.